Circulating Tumor DNA Study for Urological Cancer
Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA
Recruiting
Observational Study
Prostate Cancer
Renal Cell Cancer
Bladder Cancer
Ureter Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 20 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 3,000 (estimated)
- Sponsor
- Yonsei University · Other
Who this trial is looking for
This trial is looking for patients with bladder, prostate, renal, or ureter cancer who have had surgery in the past few years. Participants will help researchers understand how circulating tumor DNA can be used for diagnosis and monitoring their condition.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with bladder cancer
- I have been diagnosed with prostate cancer
- I have been diagnosed with renal cell cancer
- I have been diagnosed with ureter cancer
- I have had surgery for my urological cancer since December 2019
- I agree to allow my medical information to be used for this study
- I agree to participate in this study
You may not be able to join if
- I do not agree to participate in this study
- I am in a situation where I might feel pressured to join or can't make my own decisions
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Urological malignancies such as prostate cancer and renal cell cancer in Korean population have been increased due to the aged population and the westernized lifestyles. With the advancement of sequencing technologies, use of genetic mutation profiles in cancer detection and progression has been increased. However, use of circulating tumor DNA in urological malignances have been limited and few st…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* 1\. Patients diagnosed as urological malignances (prostate cancer, renal cell cancer, bladder cancer, and ureter cancer)
* 2\. Patients who have undergone surgeries due to urological malignancies in Severance Hospital, Sinchon from 2019.12 and 2029.11
* 3\. Those who agree to …
Contacts